Nemaura Medical Inc. (NMRD)
| Market Cap | 166.29M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -5.47M |
| Shares Out | 22.92M |
| EPS (ttm) | -0.25 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | March 8 |
| Last Price | $6.99 |
| Previous Close | $7.07 |
| Change ($) | -0.08 |
| Change (%) | -1.13% |
| Day's Open | 7.09 |
| Day's Range | 6.90 - 7.40 |
| Day's Volume | 52,040 |
| 52-Week Range | 3.12 - 16.50 |
Nemaura Medical Inc (NASDAQ:NMRD) has reported that it ended its third quarter with $14,959,785 in cash on the books as of December 31, 2020, up from $1,067,663 at the same stage a year earlie...
Loughborough, England, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializin...
Nemaura Medical Inc (NASDAQ:NMRD), a medical technology company focused on developing and commercializing non-invasive wearable diagnostic devices and supporting personalized lifestyle coachin...
Loughborough, England, Feb. 11, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializi...
Nemaura Medical (NMRD) stock is on the rise Monday with heavy trading despite a lack of news concerning the medical company. The post NMRD Stock: 8 Things to Know About Biopharma Nemaura Medic...
Loughborough, England, Feb. 04, 2021 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (Nasdaq: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializi...
LOUGHBOROUGH, England, Dec. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializi...
LOUGHBOROUGH, England, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializin...
LOUGHBOROUGH, England, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializin...
LOUGHBOROUGH, England, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializin...
LOUGHBOROUGH, England, Oct. 22, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializin...
Clinically proven app from Healthimation , LLC , to be paired with Company’s pro BEAT ™ non-invasive CGM system solution to offer convenient and effective management of pre-diabetes an...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD)(“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing non-invasive we...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose...
Nemaura Medical (NASDAQ: NMRD) shares are trading lower on Tuesday after the company filed for a common stock offering of 1.6 million shares.
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagno...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagno...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuous glucose...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
LOUGHBOROUGH, England--(BUSINESS WIRE)--Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagn...
There are a number of medical technology companies that have gained momentum in an otherwise pessimistic market amid the Covid-19 pandemic.
The company's continuous glucose monitor is a potential breakthrough in the diabetes diagnostics space, and also the reason why its stock has gained momentum
Loughborough, England, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company commercializing sugarBEAT®, a non-invasive and flex...
Loughborough, England, Dec. 20, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company commercializing sugarBEAT®, a non-invasive and flexible continuou...
Nemaura and Changing Health to provide innovative digital education and personalized coaching to enhance outcomes for people with diabetes and prediabetes Nemaura and Changing Health to provid...
BEAT® Diabetes utilizes SugarBEAT® CGM data to provide holistic coaching services via user-friendly app to enhance outcomes for diabetic and pre-diabetic patients BEAT® Diabetes utilizes Suga...
Loughborough, England, Dec. 04, 2019 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as a ...
Loughborough, England, Nov. 11, 2019 (GLOBE NEWSWIRE) -- – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company focused on the commercialization of SugarBEAT® as...
Loughborough, England , Sept. 12, 2019 (GLOBE NEWSWIRE) -- Loughborough, England – September 12, 2019 – Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura”), a medical technology company f...
About NMRD
Nemaura Medical, a medical technology company, discovers, develops, and commercializes diagnostic medical devices. The company provides sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as for screening pre-diabetic patients. It has a license agreement with Healthimation, LLC, which licenses the company to make, have made, use, offer to sell, sell, and import intensive medical diabetes and weight management program for Type 2 diabetes, prediabetes, and general wellness; t... [Read more...]
| Industry Medical Devices | Founded 2009 |
| CEO Dewan Chowdhury | Employees 17 |
| Stock Exchange NASDAQ | Ticker Symbol NMRD |